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DiagnosticAmyloid imaging is currently introduced to the market for clinical use. We will review the evidence demon-
strating that the different amyloid PET ligands that are currently available are valid biomarkers for
Alzheimer-related β amyloidosis. Based on recent findings from cross-sectional and longitudinal imaging
studies using different modalities, we will incorporate amyloid imaging into a multidimensional model of
Alzheimer's disease. Aside from the critical role in improving clinical trial design for amyloid-lowering
drugs, we will also propose a tentative algorithm for when it may be useful in a memory clinic environment.
Gaps in our evidence-based knowledge of the added value of amyloid imaging in a clinical context will be
identified and will need to be addressed by dedicated studies of clinical utility.
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Cognitive and behavioral decline due to neurodegenerative disease is
highly prevalent across theworld. Apart from the pervasive personal and
familial impact, the public health burden may become unsurmountable
for healthcare systems over the next decades (Brookmeyer et al., 2007;
Hebert et al., 2001) except if more efficacious interventions to prevent,
halt or slow down Alzheimer's disease (AD) (Brookmeyer et al., 1998)
are discovered. The ability to characterize directly in humans the under-
lying pathophysiological processes is fundamental to progress in AD
research and therapy. After more than a decade of therapeutic stag-
nation, the time may have come to re-think the clinical concept of
Alzheimer's disease and to re-draw the clinical development path for
testing novel candidate AD drugs. We will evaluate to which degree
the availability of amyloid imaging, amid other techniques, could alter
our clinical-diagnostic approach to AD and how this may enhance prog-
ress towards more efficacious therapy.
2. Some basic AD principles relevant to amyloid imaging
The initial abnormalities in AD probably occur at the functional
level, involving synaptic and neuronal dysfunction, possibly initiated
by abnormalities in soluble Aβ42. The exact temporal relationship
between the diverse structural alterations that follow is still a matter
of active neuropathological and in vivo research (see below). In the
revised National Institute on Aging-Alzheimer's Association (NIA-AA)
neuropathological criteria (Hyman et al., 2012), three different classifi-
cation schemes have been adopted in parallel, depending on the phase
of the spread of amyloid plaques (Thal et al., 2002) and neurofibrillary
tangles (Braak and Braak, 1991) and the amount of neuritic plaques as
defined by the Consortium to Establish a Registry for Alzheimer’s Dis-
ease (CERAD) criteria.
The principal structural changes are:
• Loss of synaptic density (Davis et al., 1999; DeKosky and Scheff,
1990; Scheff et al., 2006; Terry et al., 1991), starting in the dentate
gyrus and correlated to episodic memory scores (Scheff et al., 2006)
• Neuronal loss, starting in entorhinal cortex (Gómez-Isla et al., 1996),
and correlated to cognitive scores (Giannakopoulos et al., 2003)
• Neurofibrillary tangles (NFT) andneuropil threads (Hymanet al., 2012).
Initially, neurofibrillary tangles are mainly present in entorhinal and
perirhinal cortex spreading to the hippocampus (stage I/II). They
subsequently spread to inferior temporal and lateral temporal cortex
(stage III/IV) and then become widely distributed over neocortical
association zones (stages V/VI) (Braak and Braak, 1991; Hyman et al.,
2012; Tiraboschi et al., 2004). These NFT stages correlate relatively
well with neuronal loss and with the severity of clinical symptoms
(Arriagada et al., 1992; Bancher et al., 1993; Giannakopoulos et al.,
1998, 2003; Guillozet et al., 2003; Mesulam, 1999; Mesulam et al.,
2004).• Aβ amyloid aggregates, whichmay take different forms (Hyman et al.,
2012): According to some authors, diffuse plaques should not be con-
sidered as pathological since they are not associatedwith synapse loss
or neuronal loss, key features of Alzheimer's disease (Masliah et al.,
1990). Others have suggested that diffuse amyloid plaques are
related to the presymptomatic stage of AD (Morris et al., 1996). In
contrast to diffuse plaques, neuritic plaques stain with thioflavine S
or Bielschowsky, indicative for the presence of tau pathology invading
or surrounding the plaque. A time sequence analogous to that
described for NFTs has been developed to describe the propagation
of amyloid, starting in neocortical areas (phase 1) and then spreading
to allocortical regions including, among other regions, entorhinal
cortex, CA1, anterior and posterior cingulate (phase 2), basal forebrain
nuclei, diencephalic nuclei and striatum (phase 3), brain stem nuclei
(phase 4) and further into the molecular layer of the cerebellum
(phase 5) (Thal et al., 2002). At a certain stage the increase in β amy-
loid aggregatesmay level off, also referred to as a ‘growth arrest’ of the
amyloid plaques (Christie et al., 2001; Hyman et al., 1993).
The clinical phenotype and severity in AD is determined principally
by the topographic distribution and density of neuronal loss and NFTs,
starting in the hippocampal formation and extending into inferior and
lateral temporal cortex and beyond (Arriagada et al., 1992; Bancher
et al., 1993; Giannakopoulos et al., 1998, 2003; Guillozet et al., 2003;
Mesulam, 1999; Mesulam et al., 2004). In atypical variants of AD, such
as posterior cortical atrophy (Hof et al., 1993, 1997; von Gunten et al.,
2006) or the logopenic variant of primary progressive aphasia (Gefen
et al., 2012), the unusual clinical phenotype at initial presentation is
mirrored by an unusual distribution of neuronal loss and NFTs.
Conversely, when other proteinopathies, such as Tar DNA Binding
Protein (TDP)43-proteinopathies (Pao et al., 2011) or tauopathies
(Hornberger et al., 2012) have an atypical distribution and predom-
inantly affect medial temporal cortex, they may mimic the amnestic
presentation of AD.
As age increases, the classical hallmark lesions of AD (NFT and neu-
ritic plaques) allow one to discriminate less and less reliably between
subjects with versus without dementia (Davis et al., 1999; Prohovnik
et al., 2006). In a prospective population-based series of 456 autopsy
cases between 70 and 100 years of age (Savva et al., 2009), a strong re-
lationship between dementia and the presence of NFT and neuritic
plaqueswas seen until 75 years of age (Savva et al., 2009). This relation-
ship becameweaker above the age of 80, especially for neuritic plaques.
Diffuse plaqueswere onlyweakly associatedwith dementia, even at the
age of 75 (Savva et al., 2009). In contrast, neuropathologicalmeasures of
volume loss retained their strong relationship with the presence or
absence of dementia over the entire age range (Savva et al., 2009). Pro-
spective community-based neuropathological studies have highlighted
the contribution of other lesions to cognitive decline, such as cerebrovas-
cular lesions or Lewy bodies, independently (Schneider et al., 2012) or
interactively (Snowdon et al., 1997) with Alzheimer pathology. Cognitive
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partly independent factors, leading to the concept of ‘multifactorial AD’.
In line with this concept, NIA-AA guidelines for the neuropatho-
logic assessment of AD put emphasis on the systematic evaluation
of concomitant abnormalities, e.g. Lewy bodies, TDP43 inclusions and
vascular changes (Hyman et al., 2012). In the same vein, the novel
NIA-AA criteria for clinical AD separate out a category of possible AD
with ‘etiologically mixed’ presentation (McKhann et al., 2011). This
subgroup includes subjects who have concomitant neuropathological
findings of cerebrovascular disease, TDP43-proteinopathy or Lewy
bodies. This subgroup also includes cases where medical comorbidity
and use of drugs contribute to the cognitive dysfunction.3. Comparisons between amyloid ligands
The amyloid ligands that are available for research use are the
thioflavin T derived 11C-Pittsburgh Compound B (PIB) (Klunk et al.,
2004), its 18F-labeled analog 18F-flutemetamol (Koole et al., 2009;
Nelissen et al., 2009), the benzofuranes 11C-AZD-2184 (Nyberg
et al., 2009) and 18F-AZD-4694 (Cselényi et al., 2012), the benzoxazole
11C-BF-227 (Furukawa et al., 2010), the stilbene compounds 11C-SB
(Verhoeff et al., 2004), 18F-florbetaben (Barthel et al., 2011; Rowe
et al., 2008) and 18F-florbetapir (Wong et al., 2010), and the naph-
thol 18F-FDDNP (Small et al., 2006). Of these, at the time of writing,
only 18F-florbetapir is approved by the Food and Drugs Administration
(FDA) and European Medicines Agency (EMA) for the clinical evalua-
tion of cognitive deficits in patients. For review of the development
and biochemical characteristics of these compounds aswell asmethod-
ological nuclear imaging issueswe refer toHerholz and Ebmeier (2011),
Kadir andNordberg (2010), andMathis et al. (2012). Herewewill focus
on direct comparative studies between different amyloid ligandswithin
the same subjects (Tables 1, 2).
Verhoeff et al. (2004) compared the stilbene 11C-SB and 11C-PIB
(Verhoeff et al., 2004) (Table 1). Overall, the discriminative power was
higher for the latter compound (Table 1). Other studies compared
18F-labeled amyloid ligands to 11C-PIB (Table 2). In 20 AD and 20
amnestic MCI patients (Vandenberghe et al., 2010), volume-of-
interest based StandardizedUptakeValueRatios (SUVR)with cerebellar
gray matter as reference region were compared between 11C-PIB
and 18F-flutemetamol by means of linear regression (Table 2)
(Vandenberghe et al., 2010). There was a close match of SUVR levels
between the two compounds in neocortical volumes of interest
(Table 2). The correlationwasmuchweaker in subcortical whitematter
and pons where retention of the 18F amyloid ligand was higher than
that of 11C-PIB (Vandenberghe et al., 2010).
Wolk et al. (2012) compared 18F-florbetapir and 11C-PIB in 14 AD
and 15 healthy controls. The separation between controls and AD was
wider for 11C-PIB, both in absolute terms and in terms of S.D. (healthy
controls (HC) mean SUVR composite cortical VOI (SUVRcomp) = 1.07Table 1
Cohen's d effect size for discriminating between AD and controls (difference between
the means of the two study populations divided by the pooled standard deviation).
These values are for indicative purposes and, as indicated, may substantially vary be-
tween studies depending on the exact processing and analysis method used. For the
sake of comparison, the effect size obtained for FDG-PET for discriminating AD from




11C-PIB 2.23–3.8 Verhoeff et al. (2004), Ng et al. (2007) and
Villemagne et al. (2012)
11C-SB 1.22 Verhoeff et al. (2004)
18F-flutemetamol 2.7 Vandenberghe et al. (2010)
18F-florbetapir 2.3 Wong et al. (2010)
18F-florbetaben 1.37–3 Barthel et al. (2011) and Villemagne et al.
(2011, 2012)(SD 0.23), AD mean SUVRcomp 1.94 (SD 0.36)) than for 18F-florbetapir
(HCmean SUVRcomp 1.06 (SD 0.17), ADmean SUVRcomp 1.38 (SD 0.15)).
11C-PIB has also been directly compared with 18F-FDDNP in 14
patients with AD, 11 patients with amnestic MCI and 13 controls.
The correlation of binding potentials between the two tracers
was only 0.45 (Table 2). Values in hippocampus were higher for
18F-FDDNP than for 11C-PIB (Shin et al., 2010; Tolboom et al., 2009a).
This was also true in inferior temporal gyrus and secondary visual asso-
ciation cortex (Shin et al., 2010), probably related to the predilection of
NFTs for these regions (Giannakopoulos et al., 1998). In other neocorti-
cal association areas, binding potential values in the AD group were
more than 9-fold lower for 18F-FDDNP than for 11C-PIB, reflecting
lower affinity of 18F-FDDNP for neuritic plaques. The differences
between groups (AD, MCI and controls) were more pronounced for
11C-PIB than for 18F-FDDNP (Tolboom et al., 2009a).
It is often assumed that 18F-amyloid ligands perform more or less
equivalently for separating AD versus controls. Only direct comparisons
between the 18F-labeled amyloid ligands within the same subjects can
resolve this important question, and head-to-head comparisons are
currently underway. As several competing ligands will enter the
commercial arena, such direct comparisons will be of great clinical
interest.
4. Comparisons between amyloid ligands and neuropathology
3H-PIB colocalizes with neuritic plaques and also with diffuse
amyloid plaques and Aβ in the blood vessel wall (Lockhart et al., 2007),
andmuch less sowith tangles (Lockhart et al., 2007) or otherβ sheets ag-
gregates such as Lewy bodies (Lockhart et al., 2007). 6-CN-PIB, a highly
fluorescent derivative of 11C-PIB, has affinity for plaques (Ikonomovic
et al., 2008), more so for neuritic than for diffuse plaques (Ikonomovic
et al., 2012), as well as affinity for β amyloid in the vessel walls
(Bacskai et al., 2007) and for striatal plaques (Ikonomovic et al., 2008).
There is no affinity for cerebellar plaques and only partial affinity for
extracellular ‘ghost tangles’, probably due to adjacent neuritic plaques
(Ikonomovic et al., 2008). 11C-PIB retention values correlate with
Enzyme Linked ImmunoSorbent Assay (ELISA) measurements of Aβ42
more so than Aβ40 (Ikonomovic et al., 2012).
The level of exposure of the different types of aggregates to the
tracer may drastically differ between the brain slices and the in vivo
imaging situation (Lockhart et al., 2007). For that reason, quantitative
correlational studies between in vivomeasures of amyloid ligand reten-
tion and quantitative neuropathologicalmeasures of the presence of Aβ
are an essential step for biomarker validation.
4.1. Large-scale prospective postmortem validation studies
In the clinicopathological 18F-florbetapir phase 3 study (Clark et al.,
2011, 2012), 59 cases (mean age 79 years) received a 10-min
florbetapir PET and a neuropathological assessment within 1–2 years
following the PET (Clark et al., 2012). Twelve had no cognitive impair-
ment, 29 had clinical AD, and 13 had a clinical diagnosis of some other
form of dementia (Lewy body dementia (LDB), Parkinson's Disease
with Dementia (PDD), frontotemporal lobar degeneration (FTLD),
unspecified, mixed). When binary scan reads were compared to
binarized CERAD neuritic amyloid plaque scores (moderate/frequent
vs sparse/none), specificity was 100% and sensitivity around 92–96%.
18F-florbetapir retention levels also correlated with β amyloid area as
determined by 4G8 amyloid immunostaining (antibody against Aβ
residues 17–24). The phase 3 clinicopathological studies with the
other 18F-ligands have not been published at the time of writing.
A series of biopsy studies correlated β amyloid 4G8 immunostaining
and 18F-flutemetamol retention in normal pressure hydrocephalus.
These studies confirmed the correlation between ligand retention levels
and β amyloid plaque surface area (Leinonen et al., 2013; Rinne et al.,
2012; Wong et al., 2013).
Table 2
Within-subject correlations between 11C-PIB and 18F-labeled ligands (Tolboom et al., 2009a; Vandenberghe et al., 2010; Villemagne et al., 2012; Wolk et al., 2012). m: region-wise
linear slope. r: Pearson correlation coefficient. SUVR: Standardized Uptake Value Ratio; BP: Binding Potential. Dash: not reported.
SUVR Global BP
18F-flutemetamol 18F-florbetapir 18F-florbetaben 18F-FDDNP
r m r m r r
Composite 0.91 0.99 0.78 0.33 0.97 0.45
Frontal 0.92 1.00 0.81 – 0.94–0.96 –
Parietal 0.92 1.01 0.58 – 0.94 –
Lateral temporal 0.91 0.99 0.68 – 0.96 –
Posterior cingulate 0.91 1.01 0.79 – 0.96 –
Anterior cingulate 0.88 0.91 0.81 – 0.94 –
Medial temporal 0.83 0.74 – – 0.82 –
Occipital 0.89 1.03 – – 0.92 –
Striatum 0.84 0.88 – – 0.95 –
Subcortical white matter 0.22 0.36 – – 0.63 –
Pons 0.63 0.50 0.38 – 0.50 –
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The large-scale clinicopathological studies have been pivotal in
demonstrating the relationship between ligand retention and amyloid
plaque surface area. Smaller case series from academic investigator-
driven studies provide complimentary information to what can be
obtained from larger-scale industry-sponsored trials. A number of
cases exhibited a dissociation between amyloid positivity/negativity
and the presence/absence of Alzheimer's disease according to consen-
sus CERAD or The National Institute on Aging and Reagan Institute
(NIA-RI) neuropathological criteria. It is important to note that the
terms ‘false-positive’ and ‘false-negative’ depend on the comparator
used. If the amyloid plaque area is used as comparator and both neuritic
and diffuse plaques are counted, false-positives have not been described
until now and false-negatives only exceptionally (Cairns et al., 2009). If
conventional neuropathological criteria are used as comparator, mis-
matches will inevitably occur as these criteria also integrate other
AD-related features such as NFTs. Nevertheless, in a clinical review,
when assessing clinicopathological correlations, it is useful to compare
with such well-established nosological criteria. Conceivably, in the fu-
ture biomarker research may lead to novel taxonomic classifications
that are based on one specific lesion type (such as a diagnostic category
of β amyloidosis), among the different abnormalities that currently
define Alzheimer's disease, but such novel classifications would first
have to be validated and prove their utility in drug development and
clinical practice.
4.2.1. False-positive cases with CERAD and NIA-RI criteria as comparator
In the Baltimore Longitudinal Study of Aging (BLSA), a community-
recruited cohort is followed longitudinally with cognitive assessments
until close to time of death and brain autopsy (Driscoll et al., 2012;
Sojkova et al., 2011). In the 5 nondemented and 1 demented case
reported, 11C-PIB retention values had an almost linear relationship
with Aβ immunostaining using 6E10 antibody (which is directed at
aminoacids 1–17 of the Aβ protein). One 11C-PIB positive nondemented
case had mainly diffuse plaques, sparse neuritic plaques, and NFT Braak
stage IV. According to NIA-Reagan Institute (RI) criteria (Hyman and
Trojanowski, 1997), the likelihood of AD was low and according to
CERAD criteria for neuropathologically definite AD, the case was
normal.
Five other false-positive cases have been reported, all with a diagno-
sis of Lewy-body disease during life (Bacskai et al., 2007; Burack et al.,
2010; Kantarci et al., 2012). For instance, Burack et al. (2010) reported
3 cases with Parkinson disease dementia, two of whom had a positive
11C-PIB scan within 15 months of death. These two positive cases had
abundant diffuse plaques and only sparse neuritic plaques and interme-
diate NFT pathology (Burack et al., 2010). Neuropathologically, the
diagnosis was Braak and Braak Lewy body disease stage 6, possible ADaccording to CERAD criteria and low-probability AD according to
NIA-RI criteria (Burack et al., 2010).
Taken together, these single case reports and small case series pro-
vide evidence that despite the higher affinity of 11C-PIB for neuritic
compared to diffuse plaques (Ikonomovic et al., 2012), caseswith abun-
dant diffuse plaques and no or sparse neuritic plaques may be associat-
ed with a positive amyloid scan, although such cases would not meet
CERAD or NIA-RI neuropathological criteria for AD (Bacskai et al.,
2007; Burack et al., 2010; Kantarci et al., 2012; Sojkova et al., 2011).
4.2.2. False-negative cases with CERAD and NIA-RI criteria as comparator
Another subject of the BLSA series (Driscoll et al., 2012; Sojkova
et al., 2011) had a moderate amount of neuritic plaques according to
CERAD classification while Distribution Volume Ratio (DVR) for 11C-PIB
was only around the cut-off of 1.2. This would be considered a
false-negative scan if conventional neuropathological criteria for AD
diagnosis are used as comparator. Another case with clinically probable
Lewy body disease met CERAD criteria for definite AD due to focal de-
position of abundant neuritic plaques limited to a prefrontal region but
was 11C-PIB-negative (Ikonomovic et al., 2012). In a biopsy study of
cases with Normal-Pressure Hydrocephalus (NPH) (Leinonen et al.,
2008), one 11C-PIB-negative case met neuropathological criteria for def-
inite AD. Cairns et al. (2009) described a case above the age of 85 who
had progressive cognitive decline, a negative 11C-PIB scan, abundant dif-
fuse plaques and a neuropathological diagnosis of possible AD according
to CERAD criteria and low-probability of AD according to NIA-RI criteria
(Cairns et al., 2009). This case is not a false-negative when conven-
tional criteria are used as comparator but could be regarded as such
if the diffuse plaque count is used as comparator, as is the case in the
Katchaturian criteria (Cairns et al., 2009).
Part of the mismatch between the amyloid scan and the neuropath-
ological diagnosis can be attributed to the way neuropathologically
definite AD is defined: The regions sampled in the CERAD protocol do
not strictly match the regions of predilection of amyloid ligand re-
tention. Furthermore, in the NIA-RI criteria NFTs play an important
role which are obviously not detected by amyloid imaging. Some
neuropathologically definite PIB-negative AD cases however have neu-
ritic plaques that seem ‘11C-PIB refractory’ (Rosen et al., 2010). For
yet unknown reasons, 11C-PIB may have a low affinity for specific
and rare types of neuritic plaques (Leinonen et al., 2008). Other such
examples are the plaques occurring in the Arctic mutation carriers
(Schll et al., 2012).
4.3. Affinity for white matter lesions
White matter lesions have a highly heterogeneous neuropathologi-
cal basis. White matter lesions due to cerebral amyloid angiopathy
(CAA) would be expected to bind amyloid ligands given the affinity of
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al., 2010; Johnson et al., 2007; Lockhart et al., 2007). PIB also binds to β
sheet structures contained in myelin, e.g. myelin basic protein. This can
lead to a focal white matter signal decrease in demyelinating lesions in
multiple sclerosis (Stankoff et al., 2011). In such inflammatory condi-
tions it may be important to model changes in blood–brain-barrier
permeability that are associated with the disease as this may affect
tracer kinetics. The same could possibly be true for whitematter lesions
due to vascular disease.
4.4. Summary
Continuous measures of ‘amyloid plaque area’ highly correlate with
amyloid ligand retention values (Clark et al., 2011, 2012; Driscoll et al.,
2012; Sojkova et al., 2011). The amyloid ligands bind both neuritic and
diffuse plaques, although with higher affinity for neuritic than for
diffuse plaques (Ikonomovic et al., 2012). The three main explanations
for mismatches between binary results from amyloid ligand scans and
neuropathological CERAD or NIA-RI classification are:
1. Bindingof the amyloid ligand to diffuse plaques (Lockhart et al., 2007)
in cases where diffuse plaques are abundant and neuritic plaques
sparse or absent.
2. ‘PIB refractory cases’where affinity of the amyloid ligand for neuritic
plaques appears to be much lower for as yet poorly understood
reasons.
3. A sampling bias that is inherent to the CERAD criteria and where the
regions selected for neuropathological diagnosis do not match those
that typically show high ligand retention in vivo (such as posterior
and anterior cingulate and precuneus) (Driscoll et al., 2012).
Overall, the mismatches may be of high scientific interest but
among the total group of amyloid PET scans performed, they probably
represent only a minority of cases as evidenced by the prospective
phase 3 neuropathological studies (Clark et al., 2011, 2012).
5. The AD puzzle: putting the pieces together by means of multi-
modal imaging
Let us turn to the relationship between amyloid imaging and other
in vivo measures of AD pathology that are in clinical use (including
cognitive assessment, structural and functional MRI or FDG PET),
cross-sectionally and longitudinally. If correlations are calculated
between ligand retention levels and cognitive scores across diagnos-
tic groups (patients and cognitively intact controls), correlations
will be almost certainly found but such correlations may be indirect:
For example, as AD patients have lower cognitive scores than controls
and also higher Aβ load, a correlation of cognitive scores with Aβ load
across groups will be easily found. For a discussion of related issues
in subjects with subjective cognitive impairment (SCI) (see Chételat
et al., 2013).
5.1. Topography
Different brain regions have intrinsically different susceptibilities to
different pathological expressions of AD (Jack et al., 2008; La Joie et al.,
2012). A relatively consistent spatiotemporal pattern of volume loss
has been described using structural MRI (Baron et al., 2001; Becker et
al., 2011; Rombouts et al., 2000; Whitwell et al., 2008). According to
this ‘AD signature’ (Dickerson et al., 2009),most severe cortical thinning
occurs in rostral medial temporal and anterior temporal cortex
extending posteriorly along the middle temporalgyrus, inferior parietal
cortex, temporoparietal junction (TPJ), ventral premotor cortex and the
precuneus and posterior cingulate (Dickerson et al., 2009). The typical
topography of hypometabolism in early-stage Alzheimer's disease
versus normal controls encompasses posterior cingulate and precuneus,temporoparietal association cortex, prefrontal and ventromedial frontal
cortex, with sparing of primary sensory and motor cortex, basal ganglia
and thalami (Herholz et al., 2002; Mosconi et al., 2008).
The regional distribution of 11C-PIB retention only partly
overlaps with these well-known patterns of brain volume loss and
hypometabolism. The overlap between 11C-PIB increase and volume
loss mainly occurs in precuneus and lateral temporoparietal associa-
tion cortex in controls, amnestic MCI and AD (Jack et al., 2008). In
these regions, there is also concordance between Aβ deposition
and hypometabolism (La Joie et al., 2012; Shin et al., 2010). In hippo-
campus, however, there is a discordance between volume loss and
amyloid ligand retention: volume loss is pronounced with relatively
little Aβ deposition and limited hypometabolism. A third pattern is
seen in dorsolateral prefrontal cortex, with high ligand retention
and limited volume loss or hypometabolism (Jack et al., 2008; La
Joie et al., 2012).
Within the MCI or AD group, global 11PIB-retention levels do not
correlate with structural volume loss (Bourgeat et al., 2010; Chételat
et al., 2010). At the single-case level, several cases show dissociations
between the presence of cortical 11C-PIB retention and hippocampal
volume loss, in both directions (Jack et al., 2008; Vandenberghe et al.,
2013).
5.2. Relationship with disease severity
In AD, a structural MRI-based linear model of medial temporal, infe-
rior temporal and inferior frontal regions best predicts clinical severity,
as measured by the Clinical Dementia Rating scale—Sum of Boxes
(Dickerson et al., 2009). The pattern of hypometabolism also correlates
with the type (Engler et al., 2006) and severity (Herholz et al., 2002;
Jagust et al., 2009; Rabinovici et al., 2010) of clinical deficits in AD. In
contrast, the correlation between PET measures of Aβ deposition and
cognitive scores is weak or absent within the group of clinically proba-
ble AD subjects (Engler et al., 2006; Jagust et al., 2009; Rabinovici et al.,
2010). Within the MCI group, episodic memory scores are lower in the
amyloid-positive than the −negative MCI cases (Rowe et al., 2010;
Wolk et al., 2009). If both hippocampal volume and 11C-PIB retention
values are entered into a regression model in 39 11C-PIB-positive MCI
cases and 17 healthy controls, only hippocampal volumemake an inde-
pendent contribution to episodic memory scores (Mormino et al.,
2009).
5.3. Longitudinal change
In one of the first multimodal imaging studies with longitudinal am-
yloid imaging in controls, MCI and AD (Jack et al., 2009), ventricular ex-
pansion rate measured with MRI differed between groups (controls
1.3 cm3/yr, MCI 2.5 cm3/yr, AD: 7.7 cm3/yr). This correlated with clini-
cal decline (Jack et al., 2009). In contrast, in controls, MCI and AD, amy-
loid ligand retention only showed a small increase over time in the
absence of between-group differences (Jack et al., 2009) and without
any relationship to cognitive decline (Fouquet et al., 2009; Furst et al.,
2012; Landau et al., 2011). In MCI in particular, there was a wide vari-
ability in the amount of increase in amyloid ligand retention and in
some cases the rate of change was higher than in any of the two other
groups (Jack et al., 2009). Longitudinal studies based on FDG-PET have
demonstrated widespread metabolic changes in MCI and AD, affecting,
among other regions, posterior cingulate, precuneus, and medial tem-
poral cortex (Chen et al., 2010; Fouquet et al., 2009). These changes
correlate with longitudinal cognitive decline (Fouquet et al., 2009;
Furst et al., 2012; Landau et al., 2011).
Other studies have confirmed that the longitudinal change in Aβ de-
position in AD and MCI is relatively small. For instance, in both AD and
controls, a 3–4% increase in 11C-PIB uptake over a two-year period was
restricted tomedial frontal cortex (Scheinin et al., 2009). In a studywith
3–5 years follow-up, 11C-PIB uptake increased in MCI but remained
502 R. Vandenberghe et al. / NeuroImage: Clinical 2 (2013) 497–511stationary in the AD group, be it with considerable inter-individual
heterogeneity (Kadir and Nordberg, 2010). One of the largest longitudi-
nal studies reported so far included103 controls, 49MCI patients and 32
AD patients (Villain et al., 2012). There was a small but noticeable
increase in amyloid ligand retention over time, even in the clinical
stage. Higher rates of increase in Aβ deposition were seen with higher
baseline levels, regardless of the group, leading to the novel concept
of 11C-PIB accumulators and non-accumulators (Villain et al., 2012).
This resonates with the basic neurobiological idea of self-propagation
of Aβ deposition (Lee et al., 2010). The amount of increase in amyloid
ligand retention was regionally dependent: At baseline, precuneus
and temporoparietal junction showed the highest levels while the rate
of change was most pronounced in posterior temporal cortex (see
also Chételat et al., 2013). Between-subject variability, however, was
high, which is also apparent from visual inspection of the data (Villain
et al., 2012). Besides Aβ load at baseline, other baseline factors that
have been associated with a higher increase in Aβ load over time in
AD are APOE 4 status (Grimmer et al., 2010) and vascular white matter
lesions (Grimmer et al., 2012). The latter effect has been attributed to
reduced Aβ clearance (Grimmer et al., 2012).
Driscoll et al. (2011) evaluated whether longitudinal changes in
structural MRI over the preceding 10 years differed between amyloid-
positive versus amyloid-negative non-demented cases. No such correla-
tionwas seen at the global or the regional level, except for a trend in the
precuneus (Driscoll et al., 2011). This paper therefore shows a
within-subject dissociation between MRI structural volume loss esti-
mated over a 10-year period and amyloid ligand retention levels. In
MCI, Tosun et al. (2011) performed a parallel independent component
analysis of baseline amyloid scans and brain atrophy rates over the
subsequent year. The main components consisted of increased amyloid
levels in medial parietal regions together with higher medial temporal
atrophy rate (Tosun et al., 2011).
5.4. Comparison of diagnostic performance
From a clinical perspective, diagnostic and prognostic performance
at the individual level is the critical parameter. For instance, while
group comparisons robustly show more pronounced hippocampal
volume loss in AD patients versus controls, at the individual level
there is considerable overlap in hippocampal volumes between AD
and healthy controls (Jack and Petersen, 2000).
When the diagnostic performance of 18F-flutemetamol PET and
structural MRI is compared at the individual level in AD, MCI and
controls using machine learning techniques, overall sensitivity was
comparable between the two diagnostic techniques when the clinical
diagnosis was used as comparator (85.2%) (Vandenberghe et al.,
2013). Specificity however of the 18F-flutemetamol based classi-
fier (92%) was higher than that of the gray matter based classifier
(68%) (Vandenberghe et al., 2013). The gray matter based classifier
classified more scans from healthy controls as pathological than
the 18F-flutemetamol based classifier (Vandenberghe et al., 2013).
This could be partly explained by the overlap in hippocampal volumes
between the AD group and the controls (Duara et al., 2012; Thurfjell
et al., 2012). One of the regions that best discriminated between
Alzheimer's disease and normal controls for 18F-flutemetamol according
to the classifier's feature weights was the striatum, mainly in its anterior
portion (Vandenberghe et al., 2013). Striatum is involved in AD-relatedβ
amyloidosis from Thal stage 3 onwards (see above) (Thal et al., 2002).
Early neuropathological studies have revealed the presence of amyloid
plaques in striatum (Brilliant et al., 1997; Gearing et al., 1993; Rudelli
et al., 1984), in particular the ventral striatum (Suenaga et al., 1990).
The plaques in dorsal and ventral striatum are immunochemically
distinct from cortical plaques and also differ between dorsal and ventral
striatum, with relatively more diffuse plaques in dorsal striatum and
more dystrophic neurites in association with the plaques in ventral
striatum (Suenaga et al., 1990). Possibly, the latter pattern may relateto the connections of ventral striatum with mesolimbic and allocortical
regions and with orbitofrontal cortex (Aggleton et al., 1987; Cavada
et al., 2000; Haber et al., 1990), structures that are affected early in
the AD course by neuronal loss and tau pathology.
It is not common clinical practice in radiology to provide binary
classifications of MRI scans in relation to AD. Binary reads, however,
of FDG-PET scans are performed by nuclear medicine physicians on
a daily basis and it is therefore of clinical relevance to compare the
diagnostic accuracy of binary classification of FDG-PET with that of
amyloid PET. When clinical diagnosis (AD versus healthy controls)
is used as comparator, visual readings as well as Receiver Operating
Characterics (ROC) analysis show higher accuracy for 11C-PIB than
for FDG-PET (90% vs 70% for the reads, 95% and 83% for the ROC)
(Ng et al., 2007). Higher sensitivity and specificity of 11C-PIB than
FDG-PET was also seen in a study by Devanand et al. (2010). Values
were compared at a global level and also for the regions that showed
highest diagnostic accuracy per technique (precuneus for 11C-PIB and
parietal cortex for FDG-PET). Sensitivity and specificity of global
11C-PIB retention levels were 94% while sensitivity of mean regional
cerebral metabolic glucose rate (CMRGlu) was 81% and specificity
71%. In precuneus, sensitivity and specificity of 11C-PIB was 94%,
while sensitivity and specificity of rCMRGlu in parietal cortex was
87% and 88%, respectively (Devanand et al., 2010). In MCI, discor-
dances between 11C-PIB PET and FDG-PET were more marked and
11C-PIB PET had higher diagnostic accuracy for the distinction between
healthy controls and MCI than FDG-PET (Devanand et al., 2010).
When clinically probable AD patients (n = 62) were compared
with FTLD patients (n = 45, including behavioral variant frontotem-
poral dementia and nonfluent and semantic variants of primary
progressive aphasia (PPA)) and the clinical diagnosis was used as
standard-of-truth, sensitivity of visual reads of 11C-PIB scans for AD
(89%) was higher than that of FDG-PET (73%), with similar specificity
(83–84%) (Rabinovici et al., 2007, 2008, 2011). Interrater agreement
of the visual reads was higher for 11C-PIB (Fleiss κ 0.96) than for
FDG-PET (Fleiss κ 0.72) (Rabinovici et al., 2011). Accordingly, when
neuropathology is used as gold standard, unanimity in the overall
interpretation of FDG-PET scans between readers for discriminating
AD from FTLD was relatively low, in particular for the scans from
FTLD cases (unanimity in 7 out of 14 cases, compared to 27 out of
31 AD cases) (Womack et al., 2011). With quantitative analysis, PiB
had a higher sensitivity (89% vs 73%) but FDG a higher specificity
(83% vs 98%) (Rabinovici et al., 2011). The higher specificity probably
relates to the occurrence of positive amyloid scans even in cognitively
intact older adults. High interrater agreement (Rabinovici et al., 2011)
together with higher sensitivity (Rabinovici et al., 2011) may be
important clinical advantages that amyloid PET would bring compared
to FDG PET in the differential diagnosis between AD and FTLD, although
further studies with neuropathological diagnosis as comparator will be
required.
5.5. Task-related fMRI versus amyloid PET
Task-related fMRI can reveal adaptive changes in cognitive brain
circuits during cognitive processing which may provide resilience
against the functional impact of amyloid pathology. Brain resilience
and functional reorganization may gain importance in the field as AD
therapies may increasingly target multiple facets of AD. To the best of
our knowledge, two studies combined amyloid PET and task-related
fMRI within the same subjects in MCI or AD.
The first such study focused on changes in the language circuit in
early-stage clinically probable AD and how this related to amyloid
ligand retention (Nelissen et al., 2007). This study built on a preced-
ing study in amnestic MCI: in amnestic MCI, the earliest changes in
the language network occur in the posterior part of the left superior
temporal sulcus and these changes correlate with subclinical changes
in written word identification speed, in line with the critical role of
Table 3
Test–retest variability of SUVR for 18F-labeled amyloid ligands with cerebellum as reference region in AD patients scanned with an interval less than one month (Cselényi et al.,
2012; Joshi et al., 2012; Vandenberghe et al., 2010; Villemagne et al., 2011). Expressed in %. The exact definition of volumes of interest, e.g. the composite cortical VOI, may differ
between the studies and the current comparison should therefore be considered an indirect comparison. Dash: not reported.
18F-flutemetamol 18F-florbetapir 18F-florbetaben 18F-AZD4694
AD cases 5 10 8 3
Mean SD Mean SD Mean Range Mean SD
Composite 1.5 0.7 2.40 1.41 6.2 0.6–12.2 7.5 6.5
Frontal 1.4 0.4 – – – – – –
Parietal 2.1 1.8 – – – – – –
Lateral temporal 1.8 0.8 – – – – – –
Posterior cingulate 1.2 0.5 – – – – 7.8 5.3
Anterior cingulate 2.0 0.9 – – – – – –
Medial temporal 3.8 2.4 – – – – – –
Occipital 0.9 0.5 – – – – – –
Striatum 0.9 0.5 – – – – – –
Subcortical white matter 3.2 2.1 – – – – – –
Pons 3.1 2.7 – – – – – –
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early-stage AD, hypoactivity is also seen in left posterior temporal cor-
tex during associative-semantic versus visuoperceptual processing.
These fMRI changes in the left posterior STS in AD correlate with offline
measures of confrontation naming: clinically probable AD subjects with
hypoactivity in this region are impaired on confrontation naming
(Nelissen et al., 2007). There is no correlation between 11C-PIB levels
in this region and the clinical deficit (Nelissen et al., 2007). fMRI activity
levels to the homotopical right side show increased activity in those pa-
tients whohad preserved naming on the confrontation naming, sugges-
tive of a compensatory increase (Nelissen et al., 2007).
In the episodic memory domain, a combined 11C-PIB-fMRI study in
subjects with a Clinical Dementia Rating Scale of 0–0.5 revealed mainly
differential activity decreases as a function of Aβ deposition. During
encoding of associations between faces and names, the precuneus
and temporoparietal cortex, partially overlapping with the posterior
nodes of the default mode network, were less deactivated in amyloid-
positive subjects compared to amyloid-negative subjects (Sperling et al.,
2009). Deactivation in PCC is inversely related to hippocampal activation
(Celone et al., 2006).
5.6. Summary
Imaging techniques such as structural MRI and FDG PET reveal the
topography of structurally and functionally affected regions at an
anatomical level. This correlates with the type and degree of clinical
deficit, cross-sectionally and longitudinally. Uniquely, amyloid imag-
ing provides direct information about lesion type, yielding a superior
specificity in terms of disease diagnosis. Within the AD group, howev-
er, the extent and topographical distribution of Aβ deposition corre-
lates relatively poorly with cognitive profile, severity or progression
of the clinical deficit.
6. Amyloid imaging as a road sign in the clinical development path
6.1. Requirements
In clinical trial research, the issues related to evaluating longitudi-
nal change are similar for amyloid imaging as for any other method
(e.g. longitudinal neuropsychological assessment):
1. The change over time in the normal population and the normal vari-
ance needs to be quantified. This is necessary to determine if any
change observed in an individual, either positive or negative, falls
within the normal range or not.
2. Test–retest variability of the technique at a short interval must be
known: Test–retest variability of 11C-PIB SUVR in AD is 8.0% (SD 7)(Tolboom et al., 2009b), but can be improved to 3% by using dynamic
scans with reference tissue methods (Tolboom et al., 2009b). The
test–retest variability of the 18F-labeled amyloid ligand is provided
in Table 3 (Cselényi et al., 2012; Joshi et al., 2012; Vandenberghe et
al., 2010; Villemagne et al., 2011). To detect a drug-induced differ-
ence, test–retest variability within the same center needs to be
kept as low as possible: this will depend not only on the analysis
method (Tolboom et al., 2009b) but also on changes in structural
brain volume over time and partial volume effect, motion during
scanning etc.
3. Between-center variability should be measured: differences in scan-
ner, reconstruction algorithm etc. may affect retention levels. This is
an active area of investigationwhich is highly relevant formulticenter
trials. A European multicenter study of 11C-PIB using different scan-
ners and reconstruction algorithm suggested that the range of values
in AD, MCI and controls are relatively comparable between centers
(Nordberg et al., 2013).
4. The study drug should not affect the metrics of the technique
directly. Both in Rinne et al. (2010) and Ostrowitzki et al. (2012),
competition assays did not reveal any alteration of the tracer affinity
of amyloid plaques due to the passive immunization.
Themore fundamental question concerns the biological significance
of a change in amyloid ligand retention and how this translates into
clinical benefit given the fact that the relationship between amyloid
ligand retention and clinical expression is limited (see above). In our
view, the critical contribution of amyloid imaging to amyloid lowering
drug development lies in the selection of study patients and the demon-
stration of drug target engagement.
6.2. Patient selection
In most mono- and multicentric diagnostic trials of early-stage clini-
cally probable AD from academic memory clinics, the proportion of
AD cases with a negative amyloid PET scan is approximately 10%
(Devanand et al., 2010; Nelissen et al., 2007, 2009; Vandenberghe et
al., 2010). In other multicenter diagnostic trials these percentages have
been as high as 32% (Doraiswamy et al., 2012). In the PET substudy of
the bapineuzumab phase 2 therapeutic trial, 8 of the 53 patients screened
for inclusion did not meet 11C-PIB criteria (Rinne et al., 2010). It is likely
that similar or higher proportions of amyloid-negative cases have en-
tered amyloid-lowering drug trials as these trials most often did not
verify amyloid status at inclusion, possibly leading to dismissal of poten-
tially useful drugs. The proportion of false-positive clinical AD diagnoses
may further increase as one moves towards the predementia stage,
reducing the chance of a positive study outcome. Regardless of the
exactmechanism of action of the drug tested, improved patient selection
Table 4
Inter-reader consistency of binary reads (Fleiss' κ). Dash: not reported.
AD MCI Controls κ Reference
(n) (n) (n)
11C-PIB 15 25 0.90 Ng et al. (2007)
18F-flutemetamol 27 20 25 0.96 Vandenberghe et al. (2010)
18F-florbetapir 10 10 0.76 Joshi et al. (2012)
31 51 69 0.58 Doraiswamy et al. (2012)
18F-florbetaben 81 – 69 0.60 Barthel et al. (2011)
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will bring. This may restrict the applicability of the drug once it is
licensed. Such considerations however lose their validity in the face of
the current crisis in AD therapeutic development.6.3. Target engagement
For drugs that have as a purpose to lower amyloid levels, amyloid
imaging also allows one to evaluate target engagement. If a drug en-
gages its target but still does not exert a beneficial effect, this is highly
informative from a scientific viewpoint, while a negative trial in the
absence of any knowledge about target engagement is open to
many more interpretations. Rinne et al. (2010) and Ostrowitzki et
al. (2012) reported longitudinal changes during passive immuniza-
tion with bapineuzumab (a humanized monoclonal antibody) and
gantenerumab (a fully human monoclonal antibody), respectively
(Table 5). In both studies, the relative small sample size led to
imbalances in the 11C-PIB baseline values between groups. In the
Ostrowitzki et al. (2012) study, the highest initial SUVR value in the
placebo group was 2.3 while in the actively treated groups at least 5
subjects had values above 3, and in two of them between 3.5 and 4
(Ostrowitzki et al., 2012). This mismatch in baseline value makes in-
terpretation of differences in change between groups difficult, in par-
ticular since initial 11C-PIB level affects the subsequent rate of
increase in 11C-PIB retention (Villain et al., 2012). Furthermore, in
the Ostrowitzki et al. (2012) study, the number of infusions received
also differed between groups: two of the placebo received all 7 infu-
sions, 6 of the 60 mg group and only 1 of the 200 mg group (1 case
only two, 2 cases only 3 infusions, 2 four infusions) (Table 5). From
the report it is unclear whether the number of infusions received af-
fected the interval between first and end-of-treatment scan so that
there could be a mismatch in duration between cases. The confidence
intervals for change to baseline also included zero in all treatment
groups (Ostrowitzki et al., 2012). For these reasons one has to be cau-
tious in drawing strong conclusions from these initial studies using
11C-PIB to provide proof of target engagement by amyloid-lowering
drugs. Based on these proof-of-concept studies, one could wonder
whether prior stratification based on the biomarker value would
help prevent initial mismatches at baseline.Table 5
Numerical results from longitudinal trials with passive immunization using 11C-PIB
(Ostrowitzki et al., 2012; Rinne et al., 2010).
Number of cases Initial SUVR Observed mean difference
Bapineuzumab
Placebo 9 1.89 (0.19) +0.15
0.5, 1 or 2 mg 19 2.06 (0.20) −0.09
Ganteneurumab
Placebo 4 2.18 (0.17) +0.23
60 mg 6 2.86 (0.67) +0.02
200 mg 6 2.86 (0.63) −0.277. Amyloid imaging in clinical practice
While the validation of amyloid PET as a biomarker is relatively
advanced, there have been very few studies that directly tested its
utility (added value) and cost-effectiveness in diagnosis and patient
management in a clinical context.
7.1. Amyloid imaging and the ideal biomarker
So far, clinical development of amyloid imaging markers has
mainly focused on validating the imaging measure as a biomarker.
Ideally, AD biomarkers have to fulfill a number of requirements
(The Ronald and Nancy Reagan Research Institute of the Alzheimer
Association, 1998). The biomarker should:
1. Detect a fundamental feature of pathophysiological processes
active in AD. There is general consensus that β amyloidosis is a
fundamental feature to AD (Hardy and Selkoe, 2002). There how-
ever remains debate about the pathological nature of diffuse as
opposed to neuritic plaques (Masliah et al., 1990; Morris et al.,
1996). The selectivity of amyloid ligands for neuritic as opposed
to diffuse plaques is discussed above.
2. Be validated in neuropathologically confirmed cases. As described
above, the correlational studies with neuropathology have shown
a sensitivity of 90% and specificity of 100% (Clark et al., 2011,
2012). It remains to be seen to which degree this can be extrapo-
lated to the clinical populations in which the test would be applied.
These patients would generally be in a much earlier disease stage,
when, for instance, the relative proportion of diffuse versus neurit-
ic plaques might be different. Conversely, in advanced cases the
scans may be relatively more difficult to classify due to advance
cortical atrophy.
3. Be precise, i.e. should detect AD early in its course and distinguish it
from other dementias. For instance, in the phase 2 18F-flutemetamol
study, in which the prevalence of amyloid-positive healthy controls
was relatively low, sensitivity and specificity to discriminate AD
from controls with the clinical diagnosis as comparator was 93–96%
(Vandenberghe et al., 2010). These values vary markedly between
studies (Doraiswamy et al., 2012). This can be partly accounted for
by differences in the prevalence of positive scans in the healthy
control groups and differences in the prevalence of negative scans in
the AD group. High sensitivity and specificity values have also been
obtained in the phase 3 clinicopathological studies, which included
a variety of non-AD dementias, each in low number (Clark et al.,
2011, 2012). A growing number of papers have evaluated diagnostic
performance in AD compared to other disease groups, such as Lewy
body disease (Edison et al., 2008; Rowe et al., 2007; Villemagne et
al., 2011), cerebral amyloid angiopathy (Dhollander et al., 2011;
Dierksen et al., 2010; Johnson et al., 2007) and frontotemporal degen-
eration (Rabinovici et al., 2007, 2008, 2011; Rowe et al., 2007;
Villemagne et al., 2011) and determined sensitivity and specificity
with the clinical diagnosis as standard-of-truth (Villemagne et al.,
2011). The added value compared to clinical diagnosis will only
become clear once an independent standard-of-truth becomes avail-
able, e.g. through clinicopathological examination.
4. Should be reliable: Test–retest variability is reported in Table 3 and
interrater reliability κ in Table 4. For the sake of comparison, the
interrater reliability of visual reads of FDG-PET in 20 healthy controls
and 15 AD patients was 0.56 according to a comparative study
of 11C-PIB and FDG-PET (Ng et al., 2007), but this may improve when
statisticalmaps are used based on the contrast between an individual's
scan and a normal database rather than visual reads of native images
(Foster et al., 2007; Herholz et al., 2002; Mosconi et al., 2008).
5. Simple to perform and inexpensive: For a health system to be
sustainable given the demographic evolution, the cost of a diagnostic
technique should be outweighed by the benefit the technique brings
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therapeutic benefit but also in terms of communication of a correct
diagnosis.
6. Recommended steps to establish a biomarker include confirma-
tion by at least two independent studies from different groups of
researchers.
7.2. Clinical utility of amyloid imaging
Both amyloid imaging and CSF biomarkers directly reflect one of the
underlying neuropathological hallmark lesions of AD. The place that we
will define for these biomarkers in our tentative diagnostic algorithm
will be generally applicable to in vivo measures of AD-related amyloid-
osis, be it by means of PET or CSF (Fig. 1). The difference in utility
between imaging and biochemical biomarkers will lie in the metrics
of the tests, i.e. between-center and within-center replicability, the
prevalence of intermediate values, and the between-reader variability
in diagnostic interpretation of the values for amyloid imaging and CSF,
respectively. It has been shown that binary assignment of cases based
on 11C-PIB uptake into positive and negative cases closely corresponds
to values of Aβ42 in cerebrospinal fluid but not with any of the other
CSF variables such as total tau or Aβ40 (Fagan et al., 2006). From the
viewpoint of implementation in a clinical environment, CSF biomarkers
still have to go through the standardization steps that other diagnostic
laboratory tests, e.g. for measuring protein levels in blood, have gone
through (Bartlett et al., 2012; Mattsson et al., 2012). The values mea-
sured for a same sample vary between centers and the interpretation
of a given CSF profile may also be center- and examiner-dependent.
The factors that contribute to the between-center variability of CSF
measurements are relatively poorly understood. In this sense, the
strength of amyloid imaging compared to CSF at the time of writing
seems to lie in its performance in terms of replicability between andwith-
in centers, between-reader replicability and standardization (see above).
The occurrence of AD neuropathology in cognitively intact individ-
uals (see side-to-side review by Chételat et al. (2013)) necessarily
puts an upper limit to the maximal specificity the technique can reach
in comparison with healthy controls. The occurrence of a positive scan
in a patient who presents at the memory clinic with cognitive com-
plaints may reflect the underlying cause of cognitive dysfunction or,
alternatively, may constitute a coincidental finding given the highSignificant comorbidity
that may explain
cognitive syndrome
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Possible indications for 18 F-amyloid
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Fig. 1. Tentative clinical algorithm for the utility of amyloid imaging in patients presenting
cognitive functions or by neuropsychological evaluation. This algorithm is tentative and suprevalence of positive scans even in cognitively intact older adults in
the higher age range (see Chételat et al. (2013)).
A second clinically relevant issue is the prevalence of ‘intermediate
values’ (see also side-to-side review by Chételat et al. (2013)). This is a
classical problem in diagnostic tests, which also exists for CSF and for
FDG-PET. The number of cases within the gray zone will depend on
the population tested and may differ substantially between modalities.
The added value of biomarkers for cerebral amyloidosis depends
on:
1. The clinical context in which a diagnosis is made: primary care, neu-
rology/psychiatry/geriatrics practice, academic memory clinic, …
Different clinical contexts are associated with differences in a priori
probability of Alzheimer's disease and non-AD dementias, age differ-
ences, differences in a priori probability of comorbidity or reversible
cognitive causes, etc. These differences may affect the accuracy of a
clinical AD diagnosis and the clinical impact of an additional bio-
marker measurement.
2. The healthcare system in which amyloid imaging is implemented.
Factors that play a role and that are outside the scope of the
current review are the degree of equality of access to healthcare
that a society wishes to guarantee and budgetary restraints that
have to be put in place to be able to provide this guarantee. Bud-
getary restraints will determine the cost-benefit ratio that is
required for granting reimbursement of the biomarker.
3. The societal perception of Alzheimer's disease. The latter deter-
mines the emotional impact of an AD diagnosis on the individual's
wellbeing in the different stages of the disease course.
Paradoxically, the added value of a biomarker for β amyloidosis may
be higher in a clinical context where clinical expertise is relatively lim-
ited. Under such circumstances, the added value and cost-benefit of
amyloid imaging would have to be compared with corrective measures
directed at enhancing knowledge and clinical skills in this domain at
different healthcare levels. Nevertheless, even in centers of excellence
false-positive diagnoses of AD in the early disease stage may be more
frequent than previously assumed. For instance, awareness is increasing
that FTLDmay present initiallywith an amnestic syndrome that is hard-
ly distinguishable fromwhat is seen in AD (Hornberger et al., 2012; Pao
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(Albert et al., 2011; McKhann et al., 2011). One set of clinical criteria
is intended for use in all clinical settings. A separate set of criteria re-
fers to ‘probable or possible AD dementia or mild cognitive impair-
ment due to AD with low, high or intermediate level of evidence of
the AD pathophysiological process’. A high level is defined as a con-
cordance between markers for Aβ and markers of neuronal injury.
The latter set is for use in three circumstances: investigational use,
clinical trials (Section 5), and as optional clinical tools for use where
available and when deemed appropriate by the clinician (McKhann
et al., 2011). The topic of the remainder of this review is to delineate
a number of circumstances where the use of biomarkers may be ap-
propriate in clinical practice in our opinion.
The main clinical situations that we discern are predictive value in
MCI and differential diagnosis of AD under specific clinical circumstances.
7.3. Predictive value in MCI
Approximately 50% of MCI patients have a positive amyloid scan
(Okello et al., 2009; Pike et al., 2007; Vandenberghe et al., 2010; Wolk
et al., 2009), with highest proportions (89%) in the multidomain
amnestic MCI subtype (Wolk et al., 2009). It has been suggested that
in MCI the amyloid ligand retention values have a bimodal distribution,
but currently, to the best of our knowledge, there is no statistical proof
of such a bimodal distribution (Mormino et al., 2009). A positive amy-
loid PET has a predictive value for future conversion to Alzheimer's
disease according to early studies with follow-up periods up to 3
years (Forsberg et al., 2008; Nordberg et al., 2013; Okello et al., 2009).
In such studies, the clinician who decides about conversion to clinically
probable AD ought to be blinded to the result of the initial PET scan. The
interval over which MCI patients may convert to AD can be relatively
long and a positive scan in a subject who has not converted after a 3
or 5 year interval is not necessarily a false-positive. It is also of clinical
importance to note that a negative scan in a case with amnestic MCI
does not preclude progression. Other diseases not associated with brain
amyloidosis may cause an amnestic syndrome, such as frontotemporal
degeneration, hippocampal sclerosis, argyrophilic grain disease or
tangle-only AD. The risk for ‘conversion’ in such cases is probably as
high as for MCI due to AD. A final point relates to the clinical utility of
prediction inMCI patients in the absence of efficacious therapy. Ethical-
ly, it is important to avoid situations where the patient knows more
than what he or she would consider desirable or beneficial. Such situa-
tions could for instance be patients with a diagnosis of amnestic MCI
in whom acetylcholinesterase inhibitors are not of proven benefit and
who would receive an earlier AD diagnosis due to the diagnostic
advances.
In the phase 2 18F-florbetapir study (Doraiswamy et al., 2012), 51
MCI patients participated along with 69 healthy controls and 31 AD
patients. 37% of MCI patients were amyloid positive (Doraiswamy
et al., 2012). Forty-six of theMCI patients were followed for 18months.
This is one of the few studies that explicitly mentions blinding of the
evaluator. Of the amyloid positive MCI subjects (n = 17) 5 progressed
in an 18-months follow-up period. Of thosewhowere amyloid negative
(n = 29), 3 progressed. This study however suffers from a relatively
low sample size, short follow-up time, and a relatively poor interrater
reliability of the visual reads. Furthermore, the low prevalence of
amyloid positivity in the AD group raises concerns about the clinical
diagnostic accuracy prior to inclusion also in the MCI group.
7.4. Differential diagnosis
Accessibility of amyloid imaging in clinical practice will probably
precede the evidence for clinical utility based on strict evidence-based
medicine criteria. In our generic algorithm for use of biomarkers in an
academic memory clinic, the indications for additional biomarkers arebased on the a priori probability of Alzheimer's disease in a given indi-
vidual and the level of diagnostic certainty that one wishes to obtain.
We discern four situations where biomarker evidence may con-
tribute to the differential diagnostic process in a way that is relevant
for the patient and the caregivers concerned:
1. Early-onset dementia (onset before 60 years of age), in the ab-
sence of a known genetic mutation in the family: in early-onset de-
mentia, the a priori probability of AD as a cause of cognitive decline
is equal to that of FTLD. Furthermore, given the impact of the diag-
nosis that is communicated, a high level of diagnostic certainty is
desirable (Hodges, 2001). The impact of a correct and early diag-
nosis in young-onset dementia is situated at the personal and fa-
milial emotional and relational level, and also at the level of
third-party payers who have to make decisions on the strength
of evidence for an underlying neurological cause.
2. Atypical presentations such as PPA or predominant comportmental
disorder. Although detailed neurolinguistic phenotyping allows to
estimate the probability of AD as an underlying cause of PPA (Gorno-
Tempini et al., 2011), biomarker evidence may be very helpful. In
an early stage of the disease, subtyping of individual cases may some-
times be difficult and may require a high level of neurolinguistic ex-
pertise that may not be widely available. Even with adequate clinical
subtyping, the relationship between clinical phenotype and underly-
ing pathophysiological substrate remains probabilistic, meaning that
inferring the underlying lesion type based on the clinical phenotype
will always be liable to a substantial degree of uncertainty (Mesulam,
2000). Furthermore, when the distribution of the AD pathology is
atypical, imaging measures that reflect topography will provide less
diagnostic information than evidence based on biomarkers measuring
the underlying lesion type.
3. Cases where concomitant pathology could explain the cognitive
decline but a diagnosis of possible AD is also entertained.
• Ahigh vascular load on structuralMRI doesnot exclude the concom-
itant presence of AD. In a study of 45 cases with subcortical vascular
disease in the absence of large-vessel stroke or macrohemorrhage,
approximately one third of cases were 11C-PIB positive (Lee et al.,
2011). The amount of white matter hyperintensities correlates
with 11C-PIB based measures of Aβ load in patients with clinically
probable CAA but not in AD (Gurol et al., 2012).
• Caseswith a long-standing psychiatric history of depressionmayde-
velop Alzheimer's disease and it may be impossible to make a diag-
nosis of clinically probable AD under such conditions. A false-
negative diagnosis will lead to poor caregiver comprehension of
the drastic changes that occur over the more recent period of time
and it is important to disentangle the psychiatric origin from any ac-
quired neurodegenerative contribution. A false-positive diagnosis
would also have serious consequences in this vulnerable population.
• Medical comorbidity such as chronic renal insufficiency, heart
failure or obstructive pulmonary disease, to the degree that the
presence of AD would impact on patient management in such
cases (e.g. candidates for transplantation surgery).
• Normal-pressure hydrocephalus: Among 433 patients with a clini-
cal diagnosis of NPH based on neurological and radiological criteria,
half of whom received a ventriculoperitoneal shunt, 20% showed
cognitive decline over the following years. The presence of Aβ
alone or in combination with hyperphosphorylated tau at the
time of shunting was a strong predictor for subsequent cognitive
decline. In such cases amyloid imaging may increase preoperative
diagnostic accuracy and contribute to the decision making with
regards to a surgical intervention (Leinonen et al., 2010).
4. Rapidly progressive cognitive deterioration: There is no strict
definition of ‘rapidly progressive AD’: an interval from clinical
onset to death of less than two years would be a reasonable defini-
tion but is essentially retrospective. Besides rapidly progressive
AD, the differential diagnosis of rapidly progressive dementia
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Jakob but also potentially reversible causes such as paraneoplastic
or non-paraneoplastic autoimmune encephalitis, central nervous
system lymphoma or angiitis. To reach a high level of confidence
that reversible causes of rapid progression are excluded, hospitali-
zation and costly diagnostic investigations will often be required.
Evidence for the presence or absence of cerebral amyloidosis may
help direct the investigations. Of course, under such dramatic
conditions, biomarkers for cerebral amyloidosis will not replace
other tests such as diffusion-weighted MRI or cerebrospinal fluid
assays. The added value of biomarkers for cerebral amyloidosis in
rapidly progressive dementia is an important topic for further
investigation which will probably require a multicenter approach
given the relative rarity of this syndrome.
Under such conditions the clinical utility of amyloid imaging has to
be weighed against the clinical utility of other tools such as FDG-PET
and CSF biomarkers. Structural MRI will likely retain its place in the
diagnostic work-up, for exclusion of neoplastic lesions (basal forebrain
tumors, non-Hodgkin lymphoma, low-grade glioma ofmedial temporal
cortex…) and for assessment of the vascular lesion load. A high vascular
load may direct diagnostics and therapeutics into the vascular risk
prevention strategies. Also, if disease-modifying drugs are introduced
into the clinic,MRIGradient Echo sequencemay allow to detect cerebral
amyloid angiopathywhich is associated with a higher risk for Amyloid-
Related Imaging Abnormalities (Sperling et al., 2011), as seen in most
passive immunization trials.
Under the conditions outlined above, the benefit of amyloid imaging
is a benefit in terms of diagnostic clarity. This should not be under-
estimated as under the abovementioned conditions, accurate diagnosis
determines patientmanagement. It is also one of theprincipal questions
by patients and caregivers to the physician. It is hard to quantify this
benefit by monetary values and the benefit of accurate diagnosis early
in the disease course is a complex issue. Furthermore, with most other
diagnostics (e.g. 123I β-CIT SPECT in Parkinson's disease), there is a
clear cost-effectiveness based on appropriate therapy choices, which
is difficult for dementia when therapeutic options are still limited.
8. The multidimensional space of Alzheimer's disease
According to one of the most influential current AD models
(Jack et al., 2010, 2013), CSF alterations in Aβ42, amyloid aggregation,
MRI volume loss and cognitive decline follow an orderly temporal
sequence, initiated by changes in amyloid and culminating in the clini-
cal expression of cognitive symptoms. This model has a high heuristic
value and has engendered a number of testable hypotheses from
which a clearer picture of the time-dependent trajectories of AD
biomarkers relative to clinical disease stage and to each other will be
derived (Jack et al., 2010). This model could be viewed as a translation
of the amyloid cascade hypothesis (Hardy and Selkoe, 2002) into a
sequence of changes that are measurable in humans in vivo. Inherent
to the amyloid cascade hypothesis is a linear sequence of events that
is initiated by an amyloid related change.
Alternatives exist to such linear sequential models. For instance,
the different in vivo imaging modalities may reflect partly indepen-
dent events. According to that scenario, AD would have to be depicted
in a multidimensional space where different measures co-determine
cognitive outcome rather than as a linear sequence from Aβ42 to
cognitive symptoms. The term ‘multidimensional space’ emphasizes
the partial independence of the different in vivo measures of
Alzheimer's disease. It refers to the multidimensional scaling of sets
of parameters that is often used when one wants to discern separate
clusters within complex datasets. The multidimensional space of
Alzheimer's disease relates to the concept of multifactorial AD but re-
mains more at the level of description of the complex relationship
between different features while the term multifactorial refers moreto the factors that contribute to AD, such as neuropathological core le-
sions or concomitant Lewy bodies (see above).
A multidimensional view fits with recent genetic evidence in spo-
radic AD (Lambert et al., 2009; Sleegers et al., 2010): AD can be regarded
as a network of multiple pathways with multiple hubs that may sepa-
rately and interactively result in a given behavioral phenotype. The
multidimensional model incorporates the partial independence be-
tween processes that we can measure in vivo by means of the different
techniques, in particular between amyloid ligand retention levels and
volume loss (Driscoll et al., 2012; La Joie et al., 2012). There is also
neuropathological evidence for partial independence: Synapse loss in
dentate gyrus does not correlate with the amount of NFT (Scheff et al.,
2006) and volume loss does not correlate with amyloid load or NFT
(Driscoll et al., 2012). Such multidimensional models resonate with
the multifactorial model of AD (Savva et al., 2009) and are distinct
from an amyloidocentric linear sequential model. The way in which
different measures combine may give rise to clusters or patterns
that characterize a specific subtype of patients. The multidimensional
space therefore not only allows for partial independence between
measures but also for inter-individual heterogeneity.
The distinction between a linear sequential model and a multi-
dimensionalmodel hinges on the relative independence of the different
processes that can be imaged with current techniques. At the group
level the evidence for a probabilistic relationship between brain volume
loss, presence of amyloid aggregates, and zones of hypometabolism
is strong. At the regional and at the individual level, the inter-
dependence between these measures may be more variable. The dis-
tinction between a multidimensional and parallel model of AD versus
a linear model bears resemblance to the distinction between serial
box-and-arrow models of cognitive function and parallel distributed
models. As is the case in such neuropsychologicalmodels, linearmodels
have a strong heuristic advantage as they engender clearly defined
hypotheses that can be empirically tested. Such models have contribut-
ed a lot to our understanding of how cognitive processes are related to
each other. Multidimensional models however may allow one to cap-
ture the complexity of the brain's operations in amore truthfulmanner.
Empirical data obtained frommultimodal longitudinal studieswill have
to determine which of the two types of models is correct.
9. Conclusion
Amyloid imaging provides a direct window on one of the com-
ponents of AD. This component stands in a relatively complex relation-
ship to a diversity of other component processes. Only some of these
processes can be imaged and there is an ongoing search for techniques
to detect and quantify in vivo some of the other pathogenetic mech-
anisms, such as glial cell involvement (Cagnin et al., 2001) or tau
hyperphosphorylation (Fodero-Tavoletti et al., 2011; Okamura et al.,
2005). Potential key early aspects of AD pathophysiology, such as Aβ
oligomers, remain below the radar of current biomarker detection capa-
bilities (Jack et al., 2013). Amyloid imaging provides hope for progress
as it allows for direct measurement of one component contributing
to AD-related cognitive decline. This can enhance the chance of success
of trials by allowing to restrict inclusion to those patients who have the
target of interest and by showing whether the drug engages the target
or not. While amyloid imaging is already being introduced to the mar-
ket, many gaps can be identified in our evidence-basedmedical knowl-
edge of its role in clinical practice. These gaps will have to be filled over
the years to come by studies of clinical utility and added value.
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